My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Sep 14,2016

Net profit of Jindal Drilling & Industries declined 3.66% to Rs 9.48 crore in the quarter ended June 2016 as against Rs 9.84 crore during the previous quarter ended June 2015. Sales rose 11.24% to Rs 92.66 crore in the quarter ended June 2016 as against Rs 83.30 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales92.6683.3011
OPM %9.8912.74-
PBDT14.5518.68-22
PBT12.0915.01-19
NP9.489.84-4

Powered by Capital Market - Live News

Granules India ranks 60th in Fortune Indias list of The Next 500 Companies
Jul 24,2017

Granules India has featured at the 60th rank in Fortune Indias list of The Next 500 Companies (Mid Sized) - 2017. In addition, Granules India has also received award for being in the elite list of 25 greatest value creators in the Fortune India Next 500 universe.

Powered by Capital Market - Live News

Volumes jump at Thirumalai Chemicals counter
Jul 24,2017

Thirumalai Chemicals clocked volume of 1.09 lakh shares by 12:30 IST on BSE, a 6.8-times surge over two-week average daily volume of 16,000 shares. The stock surged 12.03% at Rs 1,190.

Videocon Industries notched up volume of 47.22 lakh shares, a 5.69-fold surge over two-week average daily volume of 8.3 lakh shares. The stock advanced 1.34% at Rs 26.40.

Jaiprakash Power Ventures saw volume of 85.91 lakh shares, a 4.57-fold surge over two-week average daily volume of 18.81 lakh shares. The stock jumped 9.85% at Rs 6.52.

Man Infraconstruction clocked volume of 22.54 lakh shares, a 4.51-fold surge over two-week average daily volume of 5 lakh shares. The stock surged 6.91% at Rs 69.65.

Aksh Optifibre saw volume of 27.86 lakh shares, a 3-fold rise over two-week average daily volume of 9.29 lakh shares. The stock galloped 10.78% at Rs 27.75.

Powered by Capital Market - Live News

Lyka Labs declines after recent sharp rally
Jul 24,2017

Meanwhile, the S&P BSE Sensex was up 191.53 points, or 0.6% at 32,220.42. The S&P BSE Small-Cap index was up 100.21 points, or 0.63% at 16,092.84.

On the BSE, 68,000 shares were traded on the counter so far as against the average daily volumes of 70,000 shares in the past two weeks. The stock had hit a high of Rs 62.70 and a low of Rs 59.20 so far during the day.

Shares of Lyka Labs had rallied 32% in the preceding seven trading sessions to settle at Rs 61.25 on Friday, 21 July 2017, from its close of Rs 46.40 on 12 July 2017.

Lyka Labs reported consolidated net profit of Rs 1.84 crore in Q4 March 2017, compared with net loss of Rs 11.99 crore in Q4 March 2016. Net sales fell 11.6% to Rs 30.60 crore in Q4 March 2017 over Q4 March 2016.

Lyka Labs is engaged in the manufacturing of pharmaceutical formulations and active pharmaceutical ingredients (APIs) across various therapeutic segments.

Powered by Capital Market - Live News

Speciality Restaurants gets tastier after opening new restaurant
Jul 24,2017

The announcement was made on Saturday, 22 July 2017.

Meanwhile, the S&P BSE Sensex was up 191.35 points or 0.6% at 32,220.24. The S&P BSE Small-Cap index advanced 102.14 points or 0.64% at 16,094.77.

On the BSE, 1,801 shares were traded on the counter so far as against the average daily volumes of 42,922 shares in the past one quarter. The stock had hit a high of Rs 116.25 and a low of Rs 111.05 so far during the day. The stock had hit a 52-week high of Rs 124.65 on 7 July 2017 and a record low of Rs 59.50 on 15 March 2017.

The stock had outperformed the market over the past one month till 21 July 2017, gaining 35.3% compared with 2.38% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 26.42% as against Sensexs 9.07% rise. The scrip had also outperformed the market in past one year, gaining 21.36% as against Sensexs 15.58% rise.

The small-cap company has equity capital of Rs 46.96 crore. Face value per share is Rs 10.

Speciality Restaurants said that as continuation of determination to dominate in Chinese and Pan Asian Market in India, the company has given birth to a new boutique oriental restaurant called POH (Progressive Oriental House).

The restaurant at Kamala Mills, Mumbai is targeted towards crn++me de la crn++me and high networth individuals (HNIs), who are looking for newer flavours and experience.

Speciality Restaurants reported net loss of Rs 9.71 crore in Q4 March 2017, higher than net loss of Rs 4.03 crore in Q4 March 2016. Net sales declined 8% to Rs 69.49 crore in Q4 March 2017 over Q4 March 2016.

Speciality Restaurants is the owner of restaurant brands like Mainland China, Flame & Grill, Machaan, Oh! Calcutta, Sigree and Haka.

Powered by Capital Market - Live News

Nucleus Software provides update on its lending mobility solution
Jul 24,2017

Nucleus Software announced the extended digitisation capability of its lending mobility solution (FinnOne Neo mCollect) which can now be used for Unified Payment Interface based direct fund transfers.

Powered by Capital Market - Live News

Alembic Pharmaceuticals gets revision in credit ratings
Jul 24,2017

Alembic Pharmaceuticals has received revision in credit ratings from CRISIL as under -

CRISIL has upgraded the Credit Rating of Long-term bank facilities from CRISIL AA/Positive to CRISIL AA+/Stable for Rs. 315 crore limit of fund/non-fund based facilities of the Company.

CRISIL has reaffirmed the Credit Rating of CRISIL A1+ (Short-term debt including Commercial Paper) for Rs. 200 crore limit of fund based facilities of the Company.

Powered by Capital Market - Live News

88 singles drugs and 33 compound formulations have been carried out under drug standardization in the year 2016-17: AYUSH Minister
Jul 24,2017

Ministry of AYUSH has set-up Central Council for Research in Ayurvedic Sciences (CCRAS) as apex body for formulation and development of Ayurvedic medicines for various diseases.

Year wise details of the study and research activities in Ayurveda including literary and conceptual study, clinical and therapeutic research and drug development research undertaken by CCRAS during the last three years and the current year are as under :-

2014-2015

i. Eight Clinical Researches completed.

ii. A total of 18 drugs were studied pharmacognostically.

iii. Under Drug Standardization, 25 singles drugs have been carried out.

iv. Toxicological study of three coded drugs completed. Biological activity of one drug completed.

v. Eight books have been published.

vi. Five Intra Mural Literary Research projects completed.

2015-2016

i. 10 Clinical Researches completed.

ii. Three Intra Mural Medicinal Plant Research projects completed.

iii. Under Drug Standardization, 54 singles drugs and 28 compound formulations have been carried out.

iv. Five Intra Mural Pharmacological Research Projects completed.

v. Eight books published. Besides this, three Intra Mural Literary Research projects completed.

2016-2017

i. Ten Clinical Researches completed.

ii. Five Intra Mural Medicinal Plant Research projects completed.

iii. Under Drug Standardization, 88 singles drugs and 33 compound formulations have been carried out.

iv. Three Intra Mural Drug Standardization Research projects completed.

v. One Intra Mural Pharmacological Research Project completed.

vi. Nine books have been published. Besides this, three Intra Mural Literary Research projects completed.

2017-2018 (upto June)

i. 20 Clinical Researches completed.

ii. Under Clinical Research, One Intra Mural Research project completed.

iii. Under Drug Standardization Programme, five IMR projects competed. Under Medicinal Plant Research, one project completed.

CCRAS has informed that toxicity has not been reported in the clinical trials conducted by them.

Rule 158-B of the Drugs & Cosmetics Rules, 1945 seeks proof of safety and effectiveness for the purpose of licensing of various categories of Ayurvedic, Siddha and Unani drugs. Enforcement of these provisions is under the purview of the State Licensing Authorities appointed by the State Governments.

Such Ayurvedic, Siddha and Unani drugs containing any of the potentially hazardous ingredients of plant, animal or mineral origin as specified in the Schedule E(1), Rule 161(2) of the Drugs and Cosmetics Rules, 1945, are required to be taken under medical supervision. In this regard an Advisory has been issued on 1st February, 2016 for Manufacturers of Ayurvedic, Siddha and Unani drugs for ensuring to imprint Caution: to be taken under medical supervision both in English and Hindi on the labels of all such Ayurvedic, Siddha and Unani drugs which contain potentially hazardous ingredients of plant, animal or mineral origin as specified in the Schedule E(1) of the Drugs and Cosmetics Rules, 1945.

There is a specific category of herbo mineral or metallic Ayurvedic medicines called Rasaushadies or Rasa yoga. Many of such medicines make use of heavy metals like Mercury, Arsenic and Lead as ingredients after subjecting them to a series of processes called Shodana, Marana, Amritkaram etc. to render them safe and therapeutically effective. Separate GMP of Rasaaushadhies have been made mandatory under the provision of Drugs & Cosmetics Rules.

Herbal Medicines are not covered in the provisions of Drugs and Cosmetics Act, 1940 and Rules there under, and hence are not recognized as a class of medicines in India. However, It is a scientific fact that the quality, efficacy, potency, shelf life and batch to batch consistency of plant material based products are affected by storage conditions. Shelf life of various categories of ayurvedic drugs is also notified under Drugs and Cosmetics Rule, 1945 and it is mandatory for the manufacturer to comply with Good Manufacturing Practices for obtaining manufacturing license.

Pharmacopoeial Standards of ayurvedic drugs are prescribed in the Ayurvedic Pharmacopoea along with permissible limit of heavy metals, aflatoxins, pesticide residue and microbial load. For manufacturing of ayurvedic products of assured quality in accordance with these standards

Powered by Capital Market - Live News

Tata Sponge Iron shines after robust Q1 result
Jul 24,2017

The result was announced after market hours on Friday, 21 July 2017.

Meanwhile, the S&P BSE Sensex was up 187.71 points or 0.59% at 32,216.60. The S&P BSE Small-Cap index was up 92.31 points or 0.58% at 16,084.94.

On the BSE, 68,000 shares were traded on the counter so far as against the average daily volumes of 44,452 shares in the past one quarter. The stock hit a high of Rs 894.70 and a low of Rs 836.80 so far during the day. The stock had hit a 52-week high of Rs 900 on 10 May 2017 and a 52-week low of Rs 474.95 on 9 November 2016.

The stock had outperformed the market over the past one month till 21 July 2017, gaining 4.96% compared with 2.38% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, rising 4.86% as against Sensexs 9.07% rise. The scrip, however, outperformed the market in past one year, gaining 33.16% as against Sensexs 15.58% rise.

The small-cap company has equity capital of Rs 15.40 crore. Face value per share is Rs 10.

Tata Sponge Iron said that the companys board of directors accorded their in principle approval for setting a steel plant of capacity upto 1.5 MTPA, in phases at Beleipada, Keonjhar District, Odisha, subject to the evaluation of financial viability of the project.

Tata Sponge Iron is a sponge iron manufacturer. Tata Steel is the promoter of Tata Sponge Iron. Tata Steel owned 54.5% stake in the company as on 30 June 2017.

Powered by Capital Market - Live News

IIFL Holdings gains strength on strong Q1 results
Jul 24,2017

The company announced its results on Saturday, 22 July 2017.

Meanwhile, the S&P BSE Sensex was up 188.65 points, or 0.6%, to 32,222.62.

On the BSE, 37,573 shares were traded in the counter so far, compared with average daily volume of 93,432 shares in the past one quarter. The stock had hit a high of Rs 617 and a low of Rs 596.75 so far during the day. The stock had hit a record high of Rs 629 on 7 June 2016. The stock had hit a 52-week low of Rs 229 on 15 November 2016.

The stock had underperformed the market over the past one month till 21 July 2017, falling 3.29% compared with 2.38% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 25.92% as against Sensexs 9.07% rise. The scrip had also outperformed the market in past one year, jumping 144.42% as against Sensexs 15.58% rise.

The large-cap company has equity capital of Rs 63.59 crore. Face value per share is Rs 2.

IIFL Holdings loan assets under management of non banking financial company business rose 26% to Rs 23330 crore in Q1 June 2017 over Q1 June 2016. Wealth assets jumped 60% to Rs 126908 crore as at 30 June 2017 over the same period last year.

Nirmal Jain, Chairman, IIFL Holdings said that in Q1 June 2017, all the companys businesses have grown well. Successful implementation of major reforms like GST and the Real Estate (Regulation and Development) Act, 2016 (RERA) has buoyed the confidence of investors, foreign and domestic alike.

Wealth management business is going from strength to strength and loan book also has seen robust growth, while maintaining high quality. The company looks forward to the rest of year with a renewed optimism, he added.

IIFL Holdings is the apex holding company of the entire IIFL Group. It offers a gamut of services including financing, wealth and asset management, broking, financial product distribution, investment banking, institutional equities, realty and property advisory services through its various subsidiaries.

Powered by Capital Market - Live News

Incap to announce Quarterly Result
Jul 24,2017

Incap will hold a meeting of the Board of Directors of the Company on 29 July 2017.

Powered by Capital Market - Live News

Bangalore Fort Farms schedules board meeting
Jul 24,2017

Bangalore Fort Farms will hold a meeting of the Board of Directors of the Company on 28 July 2017 for holding Board Meeting on 28.07.2018 for Issue of Equity Shares on Preferential Basis.

Powered by Capital Market - Live News

Smartlink Network Systems announces board meeting date
Jul 24,2017

Smartlink Network Systems will hold a meeting of the Board of Directors of the Company on 11 August 2017 un-audited Financial Results for the quarter ended 30th June, 2017.

Powered by Capital Market - Live News

Kothari Products to conduct AGM
Jul 24,2017

Kothari Products announced that the 33rd Annual General Meeting (AGM) of the company will be held on 22 September 2017.

Powered by Capital Market - Live News

Kothari Products announces board meeting date
Jul 24,2017

Kothari Products will hold a meeting of the Board of Directors of the Company on 22 July 2017.

Powered by Capital Market - Live News

Basant Agro Tech (India) to hold board meeting
Jul 24,2017

Basant Agro Tech (India) will hold a meeting of the Board of Directors of the Company on 9 August 2017 Unaudited Financial Results for the quarter ended 30.06.2017.

Powered by Capital Market - Live News